SG Americas Securities LLC Sells 11,449 Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII)

SG Americas Securities LLC cut its stake in Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating) by 21.3% during the third quarter, HoldingsChannel reports. The firm owned 42,363 shares of the medical device company’s stock after selling 11,449 shares during the period. SG Americas Securities LLC’s holdings in Cardiovascular Systems were worth $587,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Cornerstone Investment Partners LLC bought a new position in shares of Cardiovascular Systems in the second quarter worth about $159,000. Assenagon Asset Management S.A. grew its holdings in Cardiovascular Systems by 116.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 859,065 shares of the medical device company’s stock worth $12,336,000 after acquiring an additional 461,931 shares in the last quarter. Perkins Capital Management Inc. grew its holdings in Cardiovascular Systems by 3.1% during the 2nd quarter. Perkins Capital Management Inc. now owns 25,200 shares of the medical device company’s stock worth $362,000 after acquiring an additional 750 shares in the last quarter. Strs Ohio bought a new position in Cardiovascular Systems during the 2nd quarter worth about $147,000. Finally, Mutual of America Capital Management LLC grew its holdings in Cardiovascular Systems by 17.1% during the 2nd quarter. Mutual of America Capital Management LLC now owns 6,849 shares of the medical device company’s stock worth $98,000 after acquiring an additional 1,002 shares in the last quarter. 86.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. StockNews.com began coverage on shares of Cardiovascular Systems in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Lake Street Capital assumed coverage on shares of Cardiovascular Systems in a research report on Wednesday, December 14th. They set a “buy” rating and a $25.00 price target for the company. Finally, Barclays assumed coverage on shares of Cardiovascular Systems in a research report on Wednesday, December 21st. They issued an “equal weight” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Cardiovascular Systems currently has a consensus rating of “Hold” and a consensus price target of $20.00.

Cardiovascular Systems Price Performance

Shares of NASDAQ:CSII opened at $13.70 on Monday. Cardiovascular Systems, Inc. has a twelve month low of $12.26 and a twelve month high of $23.47. The company’s 50 day moving average is $13.87 and its 200 day moving average is $14.31. The company has a current ratio of 6.22, a quick ratio of 5.20 and a debt-to-equity ratio of 0.08. The company has a market cap of $573.78 million, a PE ratio of -13.70 and a beta of 0.85.

Cardiovascular Systems (NASDAQ:CSIIGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Cardiovascular Systems had a negative return on equity of 15.51% and a negative net margin of 16.40%. The business had revenue of $59.67 million during the quarter, compared to analyst estimates of $59.33 million. On average, sell-side analysts forecast that Cardiovascular Systems, Inc. will post -0.67 EPS for the current year.

About Cardiovascular Systems

(Get Rating)

Cardiovascular Systems, Inc, a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Recommended Stories

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems, Inc. (NASDAQ:CSIIGet Rating).

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.